Clinical Trials Sponsored by Janssen-Cilag G.m.b.H

Total 321 results

Janssen-Cilag International NV

Completed

Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

Multiple Myeloma
Janssen-Cilag Ltd.,Thailand

Completed

An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis

Dermatitis, Atopic

Vietnam
Janssen-Cilag Ltd.,Thailand

Completed

An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Severe Chronic Low Back Pain

Low Back Pain

Thailand
Janssen-Cilag International NV

Completed

Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics (PILAR)

Schizophrenia

Ukraine, Canada, Sweden, Czech Republic, Denmark, Thailand, Kazakhstan
Janssen-Cilag Pty Ltd

Completed

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

Dementia | Alzheimer Disease | Vascular Dementia
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Alzheimer Disease
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures

Epilepsy | Seizures
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine

Migraine Disorders
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy

Seizures, Epileptic
Vésale Hospital
Janssen-Cilag Ltd.

Completed

Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients

Prevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of Onychomycosis

Belgium
UMC Utrecht
Janssen-Cilag B.V.

Recruiting

Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The Netherlands (RAPID)

RSV Infection

Netherlands
Janssen-Cilag Ltd.
Legend Biotech

Completed

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

Multiple Myeloma

Belgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland
Kantonsspital Graubünden
Janssen-Cilag Ltd.

Completed

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients (MetAb-Pro)

Metastatic Prostate Cancer

Switzerland
Kirby Institute
Janssen-Cilag Ltd.

Completed

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (DARE-C)

Hepatitis C, Chronic

Australia
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.

Bacterial Infections | Helicobacter Infections
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux | Heartburn
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC; Janssen-Cilag G.m.b.H; Daiichi Sankyo Europe, GmbH,...

Recruiting

AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT (CONNECT)

Advanced Solid Tumor

Germany
University College, London
Janssen-Cilag Ltd.

Recruiting

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)

Waldenstrom Macroglobulinemia

United Kingdom
Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) (DETOX)

HIV Infections

Spain
Fundacion SEIMC-GESIDA
Janssen-Cilag, S.A.

Completed

Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice (CoDAR)

HIV Infections

Spain
DePuy Spine
Janssen-Cilag Pty Ltd

Completed

A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration

Early Lumbar Disc Degeneration

Australia
The Alfred
Janssen-Cilag Pty Ltd

Terminated

Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease (BNP in OAD)

Heart Failure

Australia
Janssen-Cilag Ltd.,Thailand
Mahidol University

Terminated

An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy

Anemia - Cancer Related

Thailand
Institut Claudius Regaud
Janssen-Cilag Ltd.

Terminated

Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

Breast Neoplasms

France
Institut Paoli-Calmettes
Janssen-Cilag Ltd.

Unknown

Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (PC-ARN)

Low Risk Prostate Cancer

France
Centocor, Inc.
Janssen-Cilag Farmaceutica, S.R.L.

Completed

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Melanoma

United States, United Kingdom, Germany
Institut Claudius Regaud
Janssen-Cilag Ltd.

Completed

Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

Glioblastoma Multiforme

France
University of Bologna
Janssen-Cilag Ltd.

Unknown

Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia (HEMOS AML 0106)

Acute Myeloid Leukemia

Italy
Johns Hopkins University
Janssen-Cilag Ltd.

Withdrawn

Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China, Singapore
Singapore General Hospital
Janssen-Cilag Ltd.

Completed

Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (SGH652)

Diffuse Large B-Cell Lymphoma

Singapore
Janssen-Cilag International NV
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo

Hallux Valgus

Taiwan
Imperial College London
Janssen-Cilag Ltd.

Completed

The Rilpivirine Cerebrospinal-fluid (CSF) Study

HIV

United Kingdom
Buckinghamshire Healthcare NHS Trust
Janssen-Cilag Ltd.

Completed

A Single-centre Research Study to Evaluate the Care4Today® Heart Failure Platform.

Heart Failure With Reduced Ejection Fraction
Lymphoma Study Association
Janssen-Cilag International NV

Completed

Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

France, Belgium
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (TelapreVIH)

HIV Infection | Hepatitis C, Chronic

France
Nordic Myeloma Study Group
Janssen-Cilag Ltd.

Completed

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Multiple Myeloma

Norway, Sweden, Denmark, Finland, Iceland
Intergroupe Francophone du Myelome
Janssen-Cilag Ltd.

Recruiting

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients (TEC-CARE)

Multiple Myeloma

France
University Ghent
Universiteit Antwerpen; Janssen-Cilag Ltd.

Recruiting

Integrated Depression Care (IDECA)

Depression Moderate | Depression Severe | Depression Mild

Belgium
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (FIL_DALYA)

Plasmablastic Lymphoma

Italy
University Medical Center Groningen
Janssen-Cilag B.V.

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (HiTS)

Hidradenitis Suppurativa

Netherlands
Groupe Francophone des Myelodysplasies
Janssen-Cilag Ltd.

Completed

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML (GFM-DAC-CMML)

MDS

France
Radboud University Medical Center
Janssen-Cilag Ltd.

Completed

Optimizing Abiraterone Therapy (OPTIMUM)

Metastatic Castration Resistant Prostate Cancer

Netherlands
Bnai Zion Medical Center
Janssen-Cilag Ltd.

Unknown

Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression

Ankylosing Spondylitis

Israel
Azienda Ospedaliera Universitaria Senese
Janssen-Cilag S.p.A.

Recruiting

Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM)

Myeloma Multiple

Italy
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

DLBCL

Italy
University Medical Center Groningen
Janssen-Cilag Ltd.

Completed

Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (HiGUS)

Hidradenitis Suppurativa

Netherlands
German CLL Study Group
Janssen-Cilag Ltd.

Completed

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (CLL12)

Chronic Lymphocytic Leukemia

Germany
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Terminated

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Viremia | HIV-1 Infection | Treatment Resistant Disorders

France
Foundation for Liver Research
Janssen-Cilag B.V.

Completed

Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms (ETIM)

Chronic Hepatitis C

Netherlands

3

Subscribe